In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership

Exclusive interviews with leaders at Pfizer, Sanofi and Johnson & Johnson, as well a deep dive into what nominated FDA commissioner, Robert Califf, might do when taking the helm of the US regulatory agency in 2022.

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

Business Continuity And Growth Kept In Sharp Focus At J&J Vision Care

The COVID-19 pandemic dealt a blow to Johnson & Johnson’s Vision Care business, but the company maintained its innovation program and kept customer engagement to the fore. It has started to see a return to positive contact lens buying trends, says Vision Care European business leaders Sandra Rasche and Lisa Ann Hill.

Inside Sanofi’s General Medicines Unit: Embracing A New Commercial Model

Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only. 

FDA In 2022: Califf Nominated To Retake Commissioner Role

Should Robert Califf gain a second term as US FDA commissioner, he likely will find that many of the issues demanding attention remain the same as when he left the agency five years ago, even though the names of the products now linked with them are different.

Chapter sponsored by:

End-To-End Partnerships Are Leading The Way In Drug Development

pills in factory

The speed at which new treatments have come to the pharmaceutical market for patients during COVID-19 pandemic has placed great expectation on the potential for future development.

Download Now 

About Cambrex

Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle.

Learn More »

Outlook 2022 e-Book

Outlook 2022 cover

Download a PDF copy of the Outlook 2022 collection, including Scrip 100 league tables.

ACCESS NOW
UsernamePublicRestriction

Register